$VXRT Cashflow Statement | Understand Stock

$VXRT

$0.50 +$0.00 (0.51%) Close

$VXRT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization
Gain on sale of equipment
Accretion of premium on investments
Impairment of property and equipment and right-of-use assets
Loss on disposal of property and equipment
Amortization of discount on short-term investments, net
Impairment of intangible assets
Gain on modification of lease liability
Stock-based compensation
Non-cash interest expense
Gain on remeasurement of future royalty liability
Loss on debt extinguishment
Non-cash interest expense related to sale of future royalties
Non-cash revenue related to sale of future royalties

Change in operating assets and liabilities:
Accounts receivable
Unbilled receivable from government contracts
Prepaid expenses and other assets
Prepaid clinical services, long-term
Accounts payable
Deferred revenue
Grant
Government Contract
Collaboration Revenue
Total deferred revenue
Accrued liabilities
Accrued and other liabilities
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Purchases of property and equipment
Acquisition of business, net of cash acquired
Kindred BioSciences GMP Line Acquisition
Total acquisition of business, net of cash acquired
Proceeds from sale of property and equipment
Purchases of investments
Proceeds from maturities of investments
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Net proceeds from issuance of common stock, pre-funded warrants and common warrants in underwritten offering
Proceeds from issuance of common stock upon exercise of pre-funded warrants
Proceeds from issuance of common stock upon exercise of warrants
Shares acquired to settle employee tax withholding liabilities
Proceeds from issuance of common stock upon exercise of stock options
Disgorgement of short-swing profits, net of costs
Repayment of principal on secured promissory note payable to Oxford Finance
Proceeds from issuance of common stock under the employee stock purchase plan
Proceeds from issuance of treasury stock under the employee stock purchase plan
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of the period
Cash and cash equivalents at end of the period

Supplemental disclosure of non-cash investing and financing activity:
Interest paid
Issuance of warrants to placement agents’ designees
Issuance of warrants to underwriters’ designees
Operating lease liabilities arising from obtaining right-of-use assets
Adjustment to operating lease right-of-use asset from lease modification
Acquisition of property and equipment included in accounts payable and other accrued current liabilities
Property and equipment acquired as an incentive to enter an operating lease
Lease-related assets and liabilities derecognized on early termination and modification of leases
Acquisition of property and equipment included in accounts payable and accrued expenses
Proceeds due for sale of property and equipment included in prepaid expenses and other current assets
Cash and cash equivalents
Restricted cash

Comments